Breaking News, Collaborations & Alliances

Boehringer, 3T Biosciences Partner on Next-Gen Cancer Immunotherapies

Will leverage 3T-TRACE discovery platform and Boehringer's research strategy combining cancer cell-directed and immune cell-targeting compounds.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies. The partnership will leverage 3T Biosciences’ 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer’s research strategy combining cancer cell-directed and immune cell-targeting compounds.   Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters